tiprankstipranks
Trending News
More News >
Albert David Ltd (IN:ALBERTDAVD)
:ALBERTDAVD
India Market
Advertisement

Albert David Ltd (ALBERTDAVD) AI Stock Analysis

Compare
0 Followers

Top Page

IN:ALBERTDAVD

Albert David Ltd

(ALBERTDAVD)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 4o)
Rating:51Neutral
Price Target:
₹780.00
▼(-1.07% Downside)
Albert David Ltd's overall stock score is primarily impacted by its strong balance sheet, which is overshadowed by declining financial performance and bearish technical indicators. The negative P/E ratio and low dividend yield further weigh on the valuation.
Positive Factors
Strong Balance Sheet
A strong balance sheet with low leverage and robust equity provides financial stability and reduces risk, supporting long-term resilience.
Effective Cost Management
Strong gross profit margins suggest the company manages costs well, which can sustain profitability even amid revenue fluctuations.
Strategic Partnerships
Partnerships enhance product development and market competitiveness, fostering innovation and potentially driving future revenue growth.
Negative Factors
Declining Revenue
Declining revenue impacts growth prospects and may indicate challenges in market demand or competitive positioning, affecting long-term performance.
Negative Cash Flow
Negative cash flow signals potential liquidity issues, limiting the company's ability to invest in growth opportunities and meet obligations.
Decreased Profitability
A decline in net profit margin reduces overall profitability, which can hinder reinvestment in the business and affect shareholder returns.

Albert David Ltd (ALBERTDAVD) vs. iShares MSCI India ETF (INDA)

Albert David Ltd Business Overview & Revenue Model

Company DescriptionAlbert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, bulk drugs, and disposable syringes and needles in India. It offers formulations for parenterals, oral/enteral, topical agents, and vision care products. The company also exports its products to Latin American, Southeast Asian, and other African countries. The company was incorporated in 1938 and is headquartered in Kolkata, India.
How the Company Makes MoneyAlbert David Ltd generates revenue through multiple streams, primarily by selling its medical devices and healthcare products to hospitals, clinics, and healthcare distributors. The company engages in direct sales and also leverages partnerships with key healthcare organizations and distributors to expand its market reach. Additionally, Albert David may earn revenue through service contracts, maintenance agreements, and training programs associated with their products. The company's strategic collaborations with research institutions and healthcare providers also contribute to its earnings by facilitating product development and enhancing its market competitiveness.

Albert David Ltd Financial Statement Overview

Summary
Albert David Ltd demonstrates strength in its balance sheet with low leverage and strong equity. However, declining revenue and profitability, along with negative operating and free cash flows, are critical challenges. The company must address these issues to sustain long-term growth and financial health.
Income Statement
65
Positive
Albert David Ltd has shown a mixed performance in terms of revenue and profitability. The gross profit margin is strong, indicating effective cost management, but the net profit margin has declined significantly in the latest year, reflecting a decrease in profitability. Revenue has shown fluctuations, with a notable decline in the most recent year, which is a concern for growth prospects.
Balance Sheet
78
Positive
The company's balance sheet reflects solid equity and a low level of debt, which is a positive indicator of financial stability. The equity ratio is robust, and the company has maintained a strong return on equity, although it has decreased in the latest year. The low debt-to-equity ratio limits financial risk.
Cash Flow
55
Neutral
Cash flow from operations has turned negative in the latest year, which is a significant drawback. Free cash flow also fell into negative territory, indicating potential liquidity issues. In previous years, cash flow metrics were healthier, but the recent downturn in free cash flow growth rate raises concerns about the company's ability to generate cash.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.27B3.46B3.60B3.42B3.12B2.46B
Gross Profit2.16B2.29B2.32B2.18B1.95B1.58B
EBITDA-95.32M30.26M1.05B598.68M567.76M364.59M
Net Income62.94M172.01M754.20M361.75M352.58M221.43M
Balance Sheet
Total Assets0.005.11B4.98B4.23B4.03B3.41B
Cash, Cash Equivalents and Short-Term Investments2.44B2.44B2.85B2.03B1.75B1.49B
Total Debt0.00123.17M33.24M53.18M56.62M16.19M
Total Liabilities-3.92B1.19B1.15B1.12B1.23B970.20M
Stockholders Equity3.92B3.92B3.83B3.12B2.79B2.44B
Cash Flow
Free Cash Flow0.00-432.92M346.28M52.78M292.83M349.79M
Operating Cash Flow0.00-284.36M455.02M105.15M403.65M366.11M
Investing Cash Flow0.00233.01M-332.48M-49.95M-396.97M-366.84M
Financing Cash Flow0.001.10M-82.70M-63.62M-12.59M-17.05M

Albert David Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price788.40
Price Trends
50DMA
810.67
Negative
100DMA
829.17
Negative
200DMA
841.18
Negative
Market Momentum
MACD
-9.03
Positive
RSI
44.99
Neutral
STOCH
34.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALBERTDAVD, the sentiment is Negative. The current price of 788.4 is below the 20-day moving average (MA) of 827.22, below the 50-day MA of 810.67, and below the 200-day MA of 841.18, indicating a bearish trend. The MACD of -9.03 indicates Positive momentum. The RSI at 44.99 is Neutral, neither overbought nor oversold. The STOCH value of 34.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALBERTDAVD.

Albert David Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
₹3.47B52.70-5.82%-59.22%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
₹4.56B0.63%-13.51%-122.00%
51
Neutral
₹2.89B140.694.04%-35.02%
50
Neutral
₹3.18B-1.77-30.27%-3470.06%
46
Neutral
₹3.77B-33.509.42%-12220.00%
41
Neutral
₹3.10B22.2418.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:ALBERTDAVD
Albert David Ltd
798.55
-528.95
-39.85%
IN:BROOKS
Brooks Laboratories Limited
103.50
-33.70
-24.56%
IN:LYKALABS
Lyka Labs Limited
81.01
-85.34
-51.30%
IN:NECLIFE
Nectar Lifesciences Ltd.
16.99
-17.15
-50.23%
IN:VIKASLIFE
Vikas Lifecare Limited
1.89
-2.36
-55.53%
IN:ZIMLAB
Zim Laboratories Ltd.
72.69
-40.51
-35.79%

Albert David Ltd Corporate Events

Albert David Limited Submits SEBI Compliance Certificate
Oct 7, 2025

Albert David Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate, covering the period from July 1, 2025, to September 30, 2025, was received from their Registrar & Share Transfer Agent, Maheshwari Datamatics Pvt. Ltd. The submission indicates that Albert David Limited is adhering to regulatory requirements, which is essential for maintaining investor confidence and ensuring smooth operations within the securities market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 25, 2025